Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Noemí Reguart

Showing results (31-40 of 72) with videos related to

Pageof 8
Sort By:
Cancer Science|March 13, 2024
Aberrant TIMP-1 production in tumor-associated fibroblasts drives the selective benefits of nintedanib in lung adenocarcinomaPaula Duch, Natalia Díaz-Valdivia, Marta Gabasa, et al.
Anticancer Research|October 25, 2017
Survival Outcomes According to TIMP1 and EGFR Expression in Heavily Treated Patients with Advanced Non-small Cell Lung Cancer who Received Biweekly Irinotecan Plus BevacizumabBeatriz Wills, Andrés F Cardona, Leonardo Rojas, et al.
Clinical Lung Cancer|March 23, 2019
Next-generation Sequencing for ALK and ROS1 Rearrangement Detection in Patients With Non-small-cell Lung Cancer: Implications of FISH-positive PatternsSergi Clavé, Natalia Rodon, Lara Pijuan, et al.
Carcinogenesis|October 10, 2015
Aberrant DNA methylation in non-small cell lung cancer-associated fibroblastsMiguel Vizoso, Marta Puig, F Javier Carmona, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 4, 2008
A sensitive method for detecting EGFR mutations in non-small cell lung cancer samples with few tumor cellsMiguel A Molina-Vila, Jordi Bertran-Alamillo, Noemí Reguart, et al.
Matrix Biology : Journal of the International Society for Matrix Biology|July 5, 2022
Aberrant TIMP-1 overexpression in tumor-associated fibroblasts drives tumor progression through CD63 in lung adenocarcinomaPaula Duch, Natalia Díaz-Valdivia, Rafael Ikemori, et al.
Lung Cancer (Amsterdam, Netherlands)|August 27, 2019
Stromal markers of activated tumor associated fibroblasts predict poor survival and are associated with necrosis in non-small cell lung cancerJordi Alcaraz, Josep Lluís Carrasco, Laura Millares, et al.
Cell Death & Disease|March 30, 2026
Antagonistic SMAD2/3 control of TIMP-1, VEGF-A, and hypoxia signaling in myofibroblasts shapes histotype-specific angiogenesis in lung cancerNatalia Díaz-Valdivia, Paula Duch, Rafael Ikemori, et al.
Biomaterials Science|November 4, 2025
Silicon-based nanopillars: a novel platform for tissue applicationsCristiano Piergallini, Natalia Díaz-Valdivia, Alba Deyà, et al.
Targeted Oncology|June 17, 2017
Acquired Resistance to Erlotinib in EGFR Mutation-Positive Lung Adenocarcinoma among Hispanics (CLICaP)Andrés F Cardona, Oscar Arrieta, Martín Ignacio Zapata, et al.
Pageof 8

Showing results (31-40 of 72) with videos related to

Sort By:
Pageof 8
Cancer Science|March 13, 2024
Aberrant TIMP-1 production in tumor-associated fibroblasts drives the selective benefits of nintedanib in lung adenocarcinomaPaula Duch, Natalia Díaz-Valdivia, Marta Gabasa, et al.
Anticancer Research|October 25, 2017
Survival Outcomes According to TIMP1 and EGFR Expression in Heavily Treated Patients with Advanced Non-small Cell Lung Cancer who Received Biweekly Irinotecan Plus BevacizumabBeatriz Wills, Andrés F Cardona, Leonardo Rojas, et al.
Clinical Lung Cancer|March 23, 2019
Next-generation Sequencing for ALK and ROS1 Rearrangement Detection in Patients With Non-small-cell Lung Cancer: Implications of FISH-positive PatternsSergi Clavé, Natalia Rodon, Lara Pijuan, et al.
Carcinogenesis|October 10, 2015
Aberrant DNA methylation in non-small cell lung cancer-associated fibroblastsMiguel Vizoso, Marta Puig, F Javier Carmona, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 4, 2008
A sensitive method for detecting EGFR mutations in non-small cell lung cancer samples with few tumor cellsMiguel A Molina-Vila, Jordi Bertran-Alamillo, Noemí Reguart, et al.
Matrix Biology : Journal of the International Society for Matrix Biology|July 5, 2022
Aberrant TIMP-1 overexpression in tumor-associated fibroblasts drives tumor progression through CD63 in lung adenocarcinomaPaula Duch, Natalia Díaz-Valdivia, Rafael Ikemori, et al.
Lung Cancer (Amsterdam, Netherlands)|August 27, 2019
Stromal markers of activated tumor associated fibroblasts predict poor survival and are associated with necrosis in non-small cell lung cancerJordi Alcaraz, Josep Lluís Carrasco, Laura Millares, et al.
Cell Death & Disease|March 30, 2026
Antagonistic SMAD2/3 control of TIMP-1, VEGF-A, and hypoxia signaling in myofibroblasts shapes histotype-specific angiogenesis in lung cancerNatalia Díaz-Valdivia, Paula Duch, Rafael Ikemori, et al.
Biomaterials Science|November 4, 2025
Silicon-based nanopillars: a novel platform for tissue applicationsCristiano Piergallini, Natalia Díaz-Valdivia, Alba Deyà, et al.
Targeted Oncology|June 17, 2017
Acquired Resistance to Erlotinib in EGFR Mutation-Positive Lung Adenocarcinoma among Hispanics (CLICaP)Andrés F Cardona, Oscar Arrieta, Martín Ignacio Zapata, et al.
Pageof 8